Olink®Part of Thermo Fisher Scientific
Powerful, NGS-based proteomics - effortlessly uncover meaningful insights
A unique combination of specificity and scalability enables high-throughput, multiplex protein biomarker analysis.
Next-generation high-throughput proteomics empowers genetically-informed assessment of protein causality and the confident identification of novel drug targets.
Join the growing global community and consortia of Olink users to empower your biomarker discovery.
Over 2,500 and growing rapidly – covering all major disease areas
Help shape the future of health research with Olink’s cutting-edge technology
Filters
Scientific Reports, 2025Profiling 92 circulating neurobiological proteins identifies novel candidate biomarkers of long-term cognitive outcome after ischemic stroke
Lagging C., Pedersen A., Petzold M. et al.
Olink Target 96
Angiogenesis, 2025ApoM-bound S1P acts via endothelial S1PR1 to suppress choroidal neovascularization and vascular leakage
Jung B., Yagi H., Kuo A. et al.
Olink Explore 3072/384
Parkinsonism & Related Disorders, 2025Plasma proteomic profiling reveals Parkinson's disease-associated proteins: A UK Biobank study
Jiao X., Lu Y., Huang Y. et al.
Communications Medicine, 2025Proteomics approach identifies aqueous humor biomarkers in retinal diseases
Huang K., Schofield C., Nguy T. et al.
Annals of Allergy, Asthma & Immunology, 2025Proteomic Profiling of Nasal Fluids and Serum for Type 2 Nasal Polyps Diagnosis
Hou Y., Chen C., Li Z. et al.
Nature Immunology, 2025Identification of soluble biomarkers that associate with distinct manifestations of long COVID
Gao Y., Cai C., Adamo S. et al.
International Journal of Chronic Obstructive Pulmonary Disease, 2025Plasma Levels of CXCL9 and MCP-3 are Increased in Asthma-COPD Overlap (ACO) Patients
Escamilla-Gil J., Torres-Duque C., Llinás-Caballero K. et al.
International Journal of Molecular Sciences, 2025Significant Associations Between Blood Cell Counts and Plasma Cytokines, Chemokines, and Growth Factors
Eriksson L., Eriksson M., Gordh T. et al.
Investigational New Drugs, 2025Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors
Cohen R., Jimeno A., Hreno J. et al.
Nature Communications, 2024Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis
Chitnis T., Qureshi F., Gehman V. et al.
Discover Oncology, 2025Integrating analysis of multi-omics summary data identifies novel plasma protein biomarkers and drug targets for bladder cancer
Cao J., Chen S., Wang J. et al.
Neurobiology of Disease, 2025Proximity extension assay reveals serum inflammatory biomarkers in two amyotrophic lateral sclerosis cohorts
Chen Y., Sun S., Gao N. et al.
Biomarker Research, 2025The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk
Brandão L., Zhang L., Grip A. et al.
Brain, 2025Markers of axonal injury in blood and tissue triggered by acute and chronic demyelination
Abdelhak A., Cordano C., Duncan G. et al.
Acta Neuropathologica Communications, 2025Neutrophil infiltration and microglial shifts in sepsis induced preterm brain injury: pathological insights
Zhu J., He T., Huang Z. et al.
Frontiers in Immunology, 2025Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology
Zhou X., Wang W., Chen L. et al.
hLife, 2025Systemic profiling of immune responses in healthy adults vaccinated with an RBD-targeting COVID-19 mRNA vaccine
Zhou C., Sun M., Huang X. et al.
Nature Communications, 2025Dissecting cross-population polygenic heterogeneity across respiratory and cardiometabolic diseases
Yamamoto Y., Shirai Y., Sonehara K. et al.
Neuro-Oncology, 2025A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma
Wen P., Manzanera A., Duault C. et al.
Olink Target 48
Cell Reports Medicine, 2025Cooking methods affect advanced glycation end products and lipid profiles: A randomized cross-over study in healthy subjects
Wellens J., Vissers E., Dumoulin A. et al.
2703 publications
Items per page
21-40 of 2703 publications